Here’s what you should know:
1. The company will aim to create emerging market-facing global endoscopy solutions.
2. The company is targeting the flexible endoscopy market for its growth potential. In a release, the company claims the market is currently valued at $2.5 billion, growing at a compound annual growth rate of 5 percent.
3. The company will be headquartered in Asia and will distribute products in Asia, Latin America, Eastern Europe, the Middle East and Africa.
More articles on gastroenterology:
Effector, Pfizer, Merck partner to test novel immuno-oncology agents in CRC — 4 key notes
GI center to know: Gastroenterology Consultants of Southwest Virginia
Sucampo Pharmaceuticals aims to grow Amitiza line — 4 key notes
